Central-sensitisation is a pathological amplification of pain signaling in the central nervous system where spinal dorsal horn neurons and supraspinal pain circuits become hyperexcitable, responding to normal or subthreshold stimuli as though they were noxious. This maladaptive neuroplastic transformation converts acute protective pain into chronic dysfunctional pain that persists independent of ongoing peripheral tissue damage.
Think of your home's security system. When properly calibrated, it alerts you to genuine threats—a broken window, forced entry. But imagine if the system starts "learning" from repeated false alarms. The sensors become so sensitive that a leaf brushing the window, footsteps on the sidewalk, even vibrations from traffic trigger full lockdown with sirens blaring. Eventually, the control panel itself rewires: it amplifies every signal, spreads alerts to neighbors' systems (secondary zones), and the "reset" button stops working because the circuit board has physically changed. The system meant to protect you now creates constant chaos from harmless events. Central-sensitisation is exactly this—your spinal cord and brain's pain alarm system becoming so hyperexcitable that gentle touch feels like stabbing, movement triggers agony, and the pain spreads beyond any original injury site. The neurons have literally rewired themselves to amplify danger signals, and simply treating the "broken window" (peripheral tissue) no longer stops the alarm.
Central-sensitisation develops through converging molecular cascades:
Spinal Cord Wind-Up (Primary Mechanism)
- Persistent C-fibre nociceptor activation → repeated glutamate and substance P release onto dorsal horn neurons
- Glutamate binds AMPA receptors → initial depolarization removes Mg²⁺ block from NMDA receptors
- NMDA receptor activation → massive Ca²⁺ influx into postsynaptic neuron
- Ca²⁺ activates protein kinase C (PKC), protein kinase A (PKA), and Ca²⁺/calmodulin-dependent kinase II (CaMKII)
- These kinases phosphorylate NMDA and AMPA receptors → increased receptor density and conductance
- Result: long-term potentiation (LTP) of pain pathways—each subsequent stimulus produces progressively larger responses (wind-up phenomenon)
Microglial Amplification Loop
Chronic nociceptive input → ATP and fractalkine release from neurons → P2X4 and CX3CR1 receptor activation on spinal microglia → microglial transformation from resting to activated state → release of IL-1β, TNF-α, IL-6, BDNF, and prostaglandins → these mediators act on dorsal horn neurons to:
- Increase NMDA receptor phosphorylation (TNF-α and IL-1β)
- Enhance glutamate release from primary afferents (BDNF via TrkB receptors)
- Reduce GABA and glycine inhibitory transmission (BDNF downregulates KCC2 chloride transporter → shift from hyperpolarizing to depolarizing GABA response)
Descending Modulation Imbalance
Normally: periaqueductal gray (PAG) → rostral ventromedial medulla (RVM) "off-cells" → serotonin and noradrenaline release in dorsal horn → inhibition of pain transmission
In central-sensitisation: RVM "on-cells" dominate → descending facilitation via enhanced glutamate and substance P release → further amplification of spinal excitability. Chronic stress and comorbid anxiety/depression shift this balance toward facilitation via reduced serotonin synthesis and altered 5-HT receptor expression.
Cortical Reorganization
Somatosensory cortex (S1) representation of painful body regions expands, invading adjacent territories. Anterior cingulate cortex (ACC) and insula show increased activation to identical peripheral stimuli. Reduced gray matter density in prefrontal cortex impairs top-down inhibitory control.
graph TD
A[Persistent C-fibre Input] --> B["Glutamate + Substance P Release"]
B --> C[AMPA Activation]
C --> D[NMDA Receptor Activation]
D --> E["Ca²⁺ Influx"]
E --> F[PKC/PKA/CaMKII Activation]
F --> G[Receptor Phosphorylation]
G --> H[LTP of Pain Pathways]
A --> I[ATP/Fractalkine Release]
I --> J[Microglial Activation]
J --> K["IL-1β/TNF-α/BDNF Release"]
K --> L[Neuronal Hyperexcitability]
K --> M[Loss of GABAergic Inhibition]
N[Chronic Stress] --> O[RVM On-cell Dominance]
O --> P[Descending Facilitation]
P --> L
L --> Q[Central Sensitisation]
H --> Q
M --> Q
Key Molecular Changes:
- NMDA receptor NR1 subunit phosphorylation at serine residues increases open probability
- PKCγ activation in lamina II inner neurons (specific marker of central-sensitisation)
- BDNF upregulation (3-10 fold increase in spinal cord within 24 hours of nerve injury)
- KCC2 chloride transporter downregulation → GABA becomes excitatory rather than inhibitory
- Dynorphin upregulation in spinal cord → paradoxical pronociceptive effect via NMDA receptor potentiation
Clinical Manifestations:
- Allodynia: Pain from Aβ-fibre mechanoreceptor input (normally non-painful) due to unmasking of silent synapses in dorsal horn
- Hyperalgesia: Amplified response to C-fibre input (lowered threshold from ~200 nM substance P to ~50 nM)
- Secondary hyperalgesia: Pain spreading >5 cm beyond injury site due to dorsal horn neuron receptive field expansion
- Temporal summation: 0.3 Hz C-fibre stimulation produces progressively escalating pain (normally habituates)
Central-sensitisation represents the mechanistic heart of chronic pain as disease rather than symptom—Pruimboom's "here pain slowly loses its function." Once established, it becomes self-perpetuating regardless of peripheral tissue state, explaining why patients with healed tissues or controlled inflammation (RA patients on biologics, post-surgical chronic pain) continue suffering.
cPNI Model Integration:
This exemplifies selfish nervous system behavior—the CNS prioritizes its learned threat response over peripheral reality, hijacking immune and endocrine resources to maintain the sensitized state. It reflects evolutionary mismatch: chronic pain conditions were rare in ancestral environments (acute injuries resolved or proved fatal), so our nervous system lacks "off switches" for prolonged nociceptive input. The immune amplification (microglial activation) reveals neuro-immune integration: what begins as tissue damage (immune concern) becomes neurological dysfunction requiring nervous system-targeted interventions.
Clinical Identification:
Suspect central-sensitisation when:
- Pain persists >3 months after tissue healing
- Pain disproportionate to tissue pathology on imaging
- Widespread pain from localized injury
- Allodynia (clothing, light touch causes pain)
- Temporal summation positive (repeated tapping progressively worsens pain)
- Conditioned pain modulation absent (pain elsewhere doesn't reduce test pain—suggests failed descending inhibition)
Prototype Conditions:
- fibromyalgia—widespread pain, no peripheral pathology, diagnosed via tender points representing lowered pain thresholds across body
- complex regional pain syndrome—regional pain with autonomic dysregulation, often from minor initial injury
- Chronic low back pain persisting despite disc healing
- Chronic widespread pain in 15-30% of rheumatoid arthritis patients despite TNF-α blockade controlling inflammation
Critical Threshold: Central-sensitisation can establish within 2-4 weeks of persistent nociceptive input (animal models show spinal microglial activation peaks at day 7 post-nerve injury). This creates a therapeutic window—early aggressive treatment may prevent chronification.
Intervention Implications:
Peripheral-focused treatments (NSAIDs, opioids, local injections) fail because they don't address CNS changes. Effective approaches target:
- Neuroplasticity reversal: Graded motor imagery, mirror therapy, left-right discrimination training to normalize cortical representations
- Descending inhibition restoration: Aerobic exercise activates PAG-RVM inhibitory pathways (20 minutes at 60-70% max HR reduces pain thresholds 20-30% for 30 minutes post-exercise)
- Threat reappraisal: pain neuroscience education explaining central-sensitisation reduces Pain Catastrophizing Scale scores 30-40% and pain intensity 15-25% by reducing amygdala-driven facilitation
- Neuroinflammation: omega-3 fatty acids (EPA/DHA >2g/day) reduce microglial activation and enhance specialized pro-resolving mediators (resolvins) which promote resolution of spinal neuroinflammation
- GABAergic restoration: meditation and breathwork increase prefrontal GABA levels, enhancing top-down inhibition
Biomarker Considerations:
- No direct blood test, but elevated inflammatory cytokines (IL-6 >3 pg/mL, CRP >3 mg/L) suggest ongoing neuroinflammation
- Quantitative sensory testing showing lowered pain thresholds at remote sites confirms central rather than peripheral origin
- Brain imaging: increased ACC and insula activation to fixed stimuli; reduced prefrontal gray matter
- Can develop within 2-4 weeks of persistent nociceptive input; spinal microglial activation detectable at 48 hours post-injury in animal models
- NMDA receptor phosphorylation is the initial trigger—blocking NMDA receptors during early injury phase prevents central-sensitisation development
- Substance P concentration in dorsal horn increases 5-10 fold during wind-up, with each pulse producing progressively larger neuronal responses
- BDNF acts as critical amplifier—spinal BDNF increases 300-1000% within 24 hours of nerve injury and maintains sensitization for weeks
- Microglial activation shifts spinal cord immune environment from homeostatic to inflammatory within 3-7 days of persistent pain input
- GABAergic inhibition loss is bidirectional: reduced GABA release AND conversion of GABA from inhibitory to excitatory (due to KCC2 downregulation changing chloride gradient)
- Descending facilitation from RVM can be triggered by stress, sleep deprivation, and negative affect—explaining pain flares during life stressors
- Cortical reorganization in S1 shows 25-50% expansion of painful region representation with corresponding reduction of adjacent body areas
- NSAIDs provide minimal benefit because COX-2 in CNS during central-sensitisation is modified (S-nitrosylation) and becomes refractory to traditional NSAIDs
- Opioid effectiveness decreases over time due to NMDA receptor upregulation (opioid-induced hyperalgesia shares mechanisms with central-sensitisation)
- Temporal summation threshold: normally, 1 Hz C-fibre stimulation causes stable pain; in central-sensitisation, 0.3 Hz produces escalating pain
- Secondary hyperalgesia spreads via dorsal horn neuron receptive field expansion—neurons responding only to foot now respond to ankle and calf
- chronic pain — central-sensitisation transforms acute protective pain into chronic maladaptive pain disease; the primary mechanism underlying pain chronification
- NMDA receptor — NMDA receptor activation and phosphorylation drives wind-up phenomenon; the molecular gateway to central-sensitisation establishment
- wind-up — progressive neuronal response amplification with repeated C-fibre stimulation; the temporal summation manifestation of central-sensitisation development
- BDNF — brain-derived neurotrophic factor upregulation (3-10 fold) in spinal cord enhances glutamate release and converts GABA to excitatory; maintains central-sensitisation
- Substance P — neuropeptide released from C-fibres that binds NK1 receptors on dorsal horn neurons, triggering Ca²⁺ influx and gene transcription changes
- microglia — spinal cord microglial activation releases IL-1β, TNF-α, IL-6, BDNF creating neuroinflammatory amplification loop central to persistent sensitization
- IL-1β — microglial interleukin-1β increases neuronal NMDA receptor phosphorylation and synaptic strength via IL-1R1 receptor activation
- TNF-α — tumor necrosis factor-alpha from activated microglia enhances AMPA/NMDA receptor trafficking and reduces inhibitory neurotransmission
- IL-6 — microglial IL-6 enhances nociceptor excitability and contributes to thermal hyperalgesia via gp130 receptor signaling
- dorsal horn — spinal cord laminae I-II where central-sensitisation primarily develops; second-order neurons become hyperexcitable processing hubs
- PAG — periaqueductal gray provides opioid-mediated descending inhibition; dysfunction or reduced output contributes to failed pain control in central-sensitisation
- RVM — rostral ventromedial medulla contains "on-cells" (facilitate pain) and "off-cells" (inhibit pain); balance shifts toward facilitation in central-sensitisation
- descending modulation — top-down pain control from brainstem; loss of descending inhibition and gain of descending facilitation perpetuate central-sensitisation
- allodynia — pain from normally innocuous Aβ-fibre mechanoreceptor input; hallmark of central-sensitisation due to unmasked dorsal horn synapses
- hyperalgesia — exaggerated pain response to noxious stimuli; reflects lowered activation threshold and amplified output of sensitized dorsal horn neurons
- fibromyalgia — prototype central-sensitisation syndrome with widespread pain, normal tissue pathology, and diffusely lowered pain thresholds across body
- complex regional pain syndrome — severe central-sensitisation with regional pain, autonomic dysfunction, and dramatic cortical reorganization
- rheumatoid arthritis — 15-30% of RA patients develop central-sensitisation; pain persists despite biological control of peripheral synovitis (TNF-α blockade)
- pain neuroscience education — explaining central-sensitisation mechanisms to patients reduces threat perception, amygdala activation, and pain intensity by 15-25%
- neuroplasticity — central-sensitisation represents maladaptive neuroplastic learning; interventions leverage beneficial neuroplasticity to reverse pathological changes
- exercise — graded aerobic exercise activates endogenous opioid release and brainstem descending inhibition; reduces central-sensitisation over 8-12 weeks
- chronic stress — chronic stress shifts descending modulation toward facilitation via HPA axis effects on RVM and reduces prefrontal inhibitory control
- anterior cingulate cortex — ACC shows hyperactivation in central-sensitisation; processes affective-motivational pain component and amplifies suffering
- neuroinflammation — microglial and astrocyte activation in spinal cord creates inflammatory milieu sustaining central-sensitisation independent of peripheral input
- glutamate — primary excitatory neurotransmitter released by C-fibres; activates AMPA and NMDA receptors triggering wind-up and sensitization cascades
- inflammation — peripheral inflammation triggers central-sensitisation via immune-to-brain signaling (cytokines, vagal afferents); persists after inflammation resolves
- cortisol — chronic elevation impairs glucocorticoid receptor function leading to failed immune regulation and enhanced neuroinflammation in CNS
- cognitive behavioral therapy — CBT reduces catastrophizing and threat appraisal; decreases amygdala-driven descending facilitation in central-sensitisation
- sleep — sleep deprivation enhances RVM on-cell activity and reduces pain thresholds; poor sleep perpetuates central-sensitisation
- meditation — mindfulness meditation increases prefrontal GABA levels and strengthens top-down pain inhibition; reduces central-sensitisation severity
- omega-3 fatty acids — EPA/DHA reduce spinal microglial activation and enhance resolvin production; neuroinflammation resolution in central-sensitisation